Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS)

1 day ago · Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The company’s shares closed …

$29.00
OFF

Barclays Keeps Their Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

1 day ago · Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The company’s shares closed …

businessinsider.com

$25.00
OFF

Barclays Issues A Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

Oct 17, 2024 · Barclays analyst Peter Lawson assigned a Buy rating to Arcus Biosciences (RCUS – Research Report) today and set a price target of $25.00.The company’s shares closed …

businessinsider.com

$25.00
OFF

Arcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low

2 weeks from now

2 days ago · Finally, Barclays lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. One …

marketbeat.com

$29
OFF

Arcus Biosciences Price Target Raised To $29 From $25 At Barclays

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha …

nasdaq.com

$15.83
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating Of “Buy” …

2 weeks from now

Dec 27, 2024 · Shares of RCUS opened at $15.83 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a twelve …

etfdailynews.com

$29
OFF

Arcus Anti-TIGIT Antibody Differentiated From Roche’s, Says Barclays

2 weeks from now

Nov 27, 2024 · Barclays believes TIGIT "remains a show-me story at this point" and keeps an Overweight rating on Arcus with a $29 price target. ... Read More on RCUS:Arcus Biosciences …

nasdaq.com

0%
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased By Barclays …

2 weeks from now

Dec 28, 2024 · Barclays PLC raised its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 49.0% during the third quarter, according to its most recent 13F filing with the …

americanbankingnews.com

$29.00
OFF

Barclays Sticks To Its Buy Rating For Arcus Biosciences (RCUS)

2 weeks from now

Nov 7, 2024 · Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00...

businessinsider.com

$34.25
OFF

Breaking Down Arcus Biosciences: 4 Analysts Share Their Views

2 weeks from now

Aug 9, 2024 · Analysts have recently evaluated Arcus Biosciences and provided 12-month price targets. The average target is $34.25, accompanied by a high estimate of $44.00 and a low …

nasdaq.com

0%
OFF

Barclays PLC Grows Position In Arcus Biosciences, Inc. (NYSE:RCUS)

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with …

marketbeat.com

$46
OFF

Arcus Biosciences Price Target Raised To $46 From $38 At Citi

2 weeks from now

Oct 24, 2024 · Citi analyst Yigal Nochomovitz raised the firm’s price target on Arcus Biosciences (RCUS) to $46 from $38 and keeps a Buy rating on the shares after the company presented …

nasdaq.com

FAQs about Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS) Coupon?

Is Arcus Biosciences (RCUS) a good stock to buy?

TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions. Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. ...

Is Arcus Biosciences a good buy?

Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $41.25, Arcus Biosciences has a forecasted upside of 115.7% from its current price of $19.12. ...

How much did Arcus Biosciences IPO cost?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? ...

Who owns Arcus Biosciences stock?

Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.25%), Octagon Capital Advisors LP (2.50%), Dimensional Fund Advisors LP (2.13%), Decheng Capital LLC (1.16%), Point72 Asset Management L.P. (1.03%) and Goldman Sachs Group Inc. (0.79%). ...

Where can I buy RCUS stock?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. ...